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Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone
morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular
disease and cancer. However, detailed molecular mechanisms of ALK1-mediated signalling
remain unclear. Here, we report crystal structures of the BMP10:ALK1 complex at 2.3 Å and
the prodomain-bound BMP9:ALK1 complex at 3.3 Å. Structural analyses reveal a tripartite
recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that
crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence.
Introduction of BMP10-specific residues into BMP9 yields BMP10-like ligands with diminished
signalling activity in C2C12 cells, validating the tripartite mechanism. The loss of osteogenic
signalling in C2C12 does not translate into non-osteogenic activity in vivo and BMP10 also
induces bone-formation. Collectively, these data provide insight into ALK1-mediated BMP9
and BMP10 signalling, facilitating therapeutic targeting of this important pathway.
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Bone morphogenetic proteins (BMPs) are dimeric trans-forming growth factor β (TGFβ) family cytokines, initiatingcellular signalling by forming a complex with two copies of
type I receptors and two copies of type II receptors, both of which
are type I transmembrane proteins with an intracellular serine/
threonine kinase domain. Activin receptor-like kinase 1 (ALK1) is
a type I receptor specifically expressed on endothelial cells1,
mediating the signals from BMP9 and BMP10 exclusively2. BMP
signalling can be regulated by co-receptors, such as endoglin
(ENG), as well as extracellular ligand traps, such as noggin and
crossveinless 2 (CV2)3. All TGFβ family ligands are synthesised
as preproproteins, processed by furin-like proprotein convertase
upon secretion. It has been shown for several family members,
including TGFβ, BMP9 and BMP10, that the prodomain remains
tightly bound to the growth factor (GF) domain in circulation4–6.
Hence, the prodomain may also contribute to the regulation of
BMP signalling.
BMP9 and BMP10 share a high degree of sequence identity
(64% in the GF-domain and 33% in the prodomain); both ligands
induce similar target genes in endothelial cells7 and BMP10 is
able to compensate for the function of BMP9 in Bmp9 knockout
mice7,8. Compared with other BMPs, BMP9 and BMP10 possess
several unique features. Firstly, both ligands bind to ALK1 and
ENG with sub-nanomolar affinities9,10; and the affinities of both
ligands for their cognate type I receptor ALK1 (EC50 of around
50 pg ml−1) are much higher than those of other BMPs for their
cognate type I receptors ALK2, ALK3, and ALK6 (EC50 of around
50 ng ml−1)4. Secondly, whilst several naturally-occurring extra-
cellular ligand traps have been described for BMPs, most of them
do not inhibit BMP9 or BMP10 signalling3, apart from reports
that CV2 binds to BMP9 and BMP10 and suppresses their
signalling11,12.
ALK1-mediated endothelial BMP9 and BMP10 signalling plays
many important roles in angiogenesis and the maintenance of
vascular quiescence13,14. Defects in this pathway are known to
cause cardiovascular diseases. For instance, individuals with
heterozygous loss-of-function mutations in ALK1 or ENG
develop hereditary haemorrhagic telangiectasia (HHT)15,16, and
BMP9 mutations have been identified in patients with a pheno-
type similar to HHT17. Typical HHT manifestations involve
vascular abnormalities such as arteriovenous malformations in
the brain, lung, liver, or gastrointestinal tract. In addition, het-
erozygous loss-of-function mutations in the type II BMP receptor
BMPR2, as well as in ALK1, ENG, and BMP9, have been identified
in patients with pulmonary arterial hypertension (PAH)18–21.
The pathophysiology of PAH includes endothelial dysfunction
and vascular remodelling, resulting in narrowing of pulmonary
arteries, elevated pulmonary arterial pressure and right ven-
tricular heart failure22. Importantly, targeting the endothelial
BMP pathway has promising therapeutic potential. For example,
administration of recombinant BMP9 prevented and reversed the
disease and inhibited angiogenesis in preclinical PAH models23.
Moreover, the ALK1 extracellular domain-Fc fusion protein
(ALK1-Fc, Dalantercept) and an anti-ENG antibody (TRC105)
have demonstrated anti-tumour angiogenesis activity and are
currently in phase II clinical trials for treating selected solid
tumours24–26.
A comprehensive understanding of the molecular mechanisms
behind BMP9 and BMP10 signalling will provide important
information for translating therapies that target the endothelial
BMP pathway. There are a number of questions that remain to be
answered, particularly regarding the difference between BMP9
and BMP10 as well as the regulatory role of the prodomain.
Although BMP9 and BMP10 have been shown to induce several
identical genes in endothelial cells7, no direct comparison of the
global transcription regulated by these two ligands has been
performed to date, especially by their circulating prodomain-
bound forms (pro-BMP9 and pro-BMP10, see Supplementary
Fig. 1). In addition, despite several crystal structures of BMP9
being solved, either as GF-domain alone or GF-domain in com-
plex with receptors, the co-receptor or the prodomain9,27–30,
crystal structures of BMP10 remain to be elucidated.
In this study, we directly compare global gene expression
regulated by the circulating forms of pro-BMP9 and pro-BMP10
using microarray. We report the crystal structures of BMP10 GF-
domain in complex with ALK1 to 2.3 Å and prodomain-bound
BMP9 in complex with ALK1 to 3.3 Å. Structural and sequence
analyses alongside previously reported BMP9 structures9,29,30
enable the identification of two conserved regions in BMP9 and
BMP10 that define their specificity for ALK1, ENG and their
prodomains. Furthermore, our structural analysis suggests that
CV2 does not inhibit BMP9 signalling, which we confirm by
experimental evidence, in contrast to a previous report11. Finally,
guided by the structural analysis, we modify BMP9 signalling
specificity by single amino acid substitutions. Surprisingly, we
find that in vitro alkaline phosphatase (ALP)-based osteogenic
signalling activity does not correlate with in vivo heterotopic
ossification and that previously reported non-osteogenic BMP10
can induce bone formation in vivo.
Results
Pro-BMP9 and pro-BMP10 are equivalent ALK1 ligands.
Although pro-BMP9 and pro-BMP10 are the in vivo circulating
forms of ligands4,5, most of the previous signalling and functional
studies on BMP9 and BMP10 have employed the GF-domain
alone. Thus, it is essential to establish whether pro-BMP9 and
pro-BMP10 bind to ALK1 and signal in endothelial cells in the
same manner as their GF-domains. We first compared whether
pro-BMP9 and pro-BMP10 can signal with similar potency to
their GF-domains. As shown in Fig. 1a, in a dose-response assay
in human pulmonary artery endothelial cells (PAECs) using
Inhibitor of DNA binding protein 1 (ID1) gene induction as a
readout, pro-BMP9 and pro-BMP10 exhibited identical potency
to BMP9 and BMP10 GF-domains, respectively.
We then carried out a microarray experiment to establish
whether there is any differential gene induction by pro-BMP9 and
pro-BMP10 in endothelial cells. As shown in Fig. 1b–d and
Supplementary Data 1 and 2, both pro-BMP9 and pro-BMP10
induced and suppressed similar transcript expression when
compared with PBS-treated controls; indeed, there was no
significant difference in gene induction or suppression when
comparing pro-BMP9 with pro-BMP10, providing evidence that
they are functionally equivalent ALK1 ligands in vitro on
endothelial cells. We further compared the ALK1 binding affinity
of pro-BMP9 and pro-BMP10 to that of BMP9 and BMP10,
respectively, using surface plasmon resonance (SPR). As shown in
Fig. 1e, f, the KD values measured for BMP9:ALK1-Fc and
BMP10:ALK1-Fc (48.1 pM and 34.3 pM, respectively) were very
similar to those previously reported (45.22 pM and 10.3 pM,
respectively)9. In addition, both BMP9 and BMP10 bound to the
ALK1 monomer (produced in house)28 and dimer (ALK1-Fc)
with similar affinities, irrespective of the presence of their
prodomains (Fig. 1e, f), which supported the findings from
Fig. 1a that the prodomain does not interfere with ALK1-
mediated signalling potency.
Structure of BMP10:ALK1 complex. To delineate the molecular
details of ALK1-mediated BMP10 signalling, we solved the crystal
structure of the BMP10 GF-domain in complex with the ALK1
extracellular domain (ECD) to 2.3 Å (Fig. 2a and Supplementary
Table 1; Supplementary Figs. 2, 3). As expected, the ALK1 ECD
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ALK1-Fc (dimer) ALK1 ECD (monomer)
ka (M–1 s–1) kd (s–1) KD (pM) ka (M–1 s–1) kd (s–1) KD (pM)
BMP9 1.29 ×106 6.19 × 10–5 48.1 1.17 × 106 8.37 × 10–5 71.6
Pro-BMP9 7.91 × 105 4.84 × 10–5 61.2 9.10 × 105 8.46 × 10–5 92.9
BMP10 1.54 × 106 5.31 × 10–5 34.3 1.53 × 106 8.50 × 10–5 55.7
Pro-BMP10 3.07 × 106 3.44 × 10–5 11.2 3.32 × 106 5.63 × 10–5 17.0
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Fig. 1 Pro-BMP9 and pro-BMP10 are equivalent ALK1-ligands. a Dose-dependent signalling assays in PAECs. Serum-starved PAECs were treated with
different ligands at 2.48 pM (white bars), 8.27 pM (light grey bars) and 27.3 pM (dark grey bars) (using monomer molecular weight, equivalent to 0.03, 0.1
and 0.33 ngml−1 BMP9 GF-domain concentration) for 1 h. Changes in the ID1 gene expression were monitored using RT-qPCR. Data were presented
as fold change relative to untreated cells, and means ± SEM of three independent experiments are shown. Source data are provided as a Source Data file.
b–d Volcano plots comparing changes in global gene expression in PAECs after pro-BMP9 or pro-BMP10 treatment. Serum-starved PAECs were treated
with 25 pM of pro-BMP9 or pro-BMP10 (purity can be found on SDS-PAGE with silver staining in Supplementary Fig. 8a, lanes 1 and 4) for 1.5 h before RNA
was extracted for microarray analysis. Four different primary PAEC lines were used. Red dots above the dashed line represent the changes in target genes
with adjusted p values of less than 0.05. Several representative target genes are highlighted in c and d. Full list of genes can be found in Supplementary
Data 1 and 2. e Affinity measurements of BMP9 and BMP10 for ALK1 using Biacore. A CM5 Biacore chip was immobilised with ALK1 dimer (ALK1-Fc) or
monomer (in-house purified ALK1 ECD, purity can be seen in Supplementary Fig. 8a, lane 7). The sensorgrams of BMP9, pro-BMP9, BMP10 and pro-
BMP10 binding raw data (in black lines) were overlaid with a global fit to a 1:1 model with mass transport limitations (red lines). f A summary of kinetic
parameters for ligand-receptor interactions derived from the Biacore measurements in e.
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binds BMP10 in a 2:2 stoichiometry, and the two ALK1 ECD
monomers are not in direct contact. The assembly of BMP10:
ALK1 is identical to that of BMP9:ALK1 in the BMP9:ALK1:
ActRIIb complex (PDB:4FAO), with mainchain root-mean-
square deviation (RMSD) of 0.84 Å for BMP dimer, 0.52 Å for
ALK1 monomer. The total buried surface area of the BMP10:
ALK1 interface is slightly smaller than that of the BMP9:ALK1
interface (Fig. 2b), however, the percentage of contribution from
the two monomers is similar. Importantly, the ALK1 binding sites
on BMP9 and BMP10 are mostly conserved, which corresponds
well with the above data that these ligands bind ALK1 with
comparable affinity and stimulate ALK1-dependent signalling in
endothelial cells with similar potency.
Specificity determinants in the BMP9 and BMP10 subfamily.
The high affinity of BMP9 and BMP10 for ALK1 and their spe-
cificity for ALK1-mediated signalling suggest that these ligands
possess common specificity determinants. The crystal structure of
the BMP10:ALK1 complex, alongside the previously reported
complex structures of BMP99,29,30, provide a unique opportunity
to identify such specificity determinants.
Most BMPs have higher affinities for the type I receptors, such
as BMP2 and BMP4 for ALK3, BMP9 and BMP10 for ALK1, and
BMP14 (also called GDF5) for ALK6. The exceptions are BMP6
and BMP7, which signal via ALK2 but bind to the Activin type II
receptors a and b (ActRIIa and ActRIIb) with higher affinity.
Among the four type I receptors that are known to mediate BMP
signalling, the high affinity ligands for ALK1, ALK3 and ALK6
have been described and crystal structures of these receptors
bound to their cognate ligands been solved9,31,32, whereas the
existence of high affinity ligand(s) for ALK2 is yet to be
confirmed.
A close examination of sequence alignment between the five
representative BMPs with high affinities for the type I receptors as
well as BMP6 and BMP7 revealed a total of 16 residues that are
preferentially conserved between BMP9 and BMP10 (Fig. 3a,
highlighted in cyan, blue and yellow). Interestingly, these residues
can be mapped onto three regions of BMP10 (Fig. 3b, c), the type
I receptor-binding site, the type II receptor-binding site and the
middle of the BMP dimer interface.
The type I receptor binding site and conserved region 1. Using
the PDBePISA server33, a total of 26 BMP10 residues were
identified at the ALK1 binding interface (Fig. 3a, lines over the
sequence). Interestingly, these residues can be divided into three
groups (Fig. 4a): those conserved across different subgroups of
BMPs (in red, also * over the top of the sequence in Fig. 3a), those
conserved only among BMP9 and BMP10 (in cyan, referred to as
conserved region 1) and those that vary between BMP9 and
BMP10 (in yellow). The interactions between BMP10 and ALK1
cover the same three sites as previously identified between BMP9
and ALK1 in the 3.35 Å BMP9:ALK1:ActRIIb structure9, but the
2.3 Å resolution reveals the BMP10:ALK1 interface in more detail
(Fig. 4b–f). Sites II and III within the type I receptor binding area,
which have been proposed to hold the key to ALK1 specificity for
BMP99, indeed harbour the residues unique to BMP9 and BMP10
(Fig. 4c, d, cyan). At the site II, ALK1-specificity is defined by
a hydrogen bond (H-bond) between BMP10 S339 and the
mainchain oxygen of ALK1 R78, and a salt bridge between
BMP10 D338 and ALK1 R80. Site III contains two residues
conserved between BMP9 and BMP10 that contribute to the
ALK1 specificity, but they differ in molecular interactions in the
two complexes. While ALK1 H73 forms a H-bond with BMP10
P366, ALK1 E75 forms a H-bond with Y413 which is conserved
across all BMPs. Overlaying the BMP2:ALK3 structure31 revealed
that although the equivalent residue Y385 in BMP2 makes a
similar H-bond with ALK3 D84, there is a significant movement
in BMP10 mainchain conformation due to the unique insertion
of F411 (and Y416 in BMP9, Fig. 3a). Thus K368, the BMP9 and
BMP10-specific residue, defines the ALK1 specificity by inter-
acting with the mainchain oxygen on the BMP10 loop, allowing
Y413 to be in close proximity for interacting with ALK1.
a
b
Buried Surface on ALK1 (Mol C) Buried Surface on BMP
Total (Å2) Total (Å2)% contribution 
from BMP Mol A
% contribution from 
BMP Mol B
% contribution from 
BMP Mol A
% contribution from 
BMP Mol B
BMP10:ALK1 1072.2 37.0 63.0 1025.5 32.5 67.5
BMP9:ALK1 1193 34.6 65.4 1121.4 30.9 69.1
Mol A 
Mol B
Mol C 
Fig. 2 Crystal structure of human BMP10:ALK1 complex at 2.3 Å. a Crystal structure of BMP10 (cyan) in complex with ALK1 (magenta), overlaid with the
structure of BMP9:ALK1:ActRIIb complex (PDB:4FAO, in grey and semi-transparent). Mol A and Mol B are the two BMP monomers whose interfaces with
ALK1 (Mol C) were analysed in b. b Comparison of the buried interface upon complex formation between BMP10:ALK1 and BMP9:ALK1 (from 4FAO). Total
buried surface area and the contributing residues were calculated using PDBePISA server.
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Reciprocally, ALK1 evolved a negatively charged residue with a
longer side-chain at the corresponding position, E75, to allow the
H-bond formation with Y413, defining its specificity for BMP9
and BMP10. The site I region contains residues that are different
between BMP9 and BMP10, with the interactions predominantly
mediated by sidechains (Fig. 4e). In contrast, the core of the
interface is conserved across all BMPs and mostly hydrophobic in
nature (Fig. 4f). From the ALK1 side, residues H73, E75, R78 and
R80 interact with amino acids that are unique to BMP9 and
BMP10 hence define the ALK1 specificity (Fig. 4c, d). Interest-
ingly, these ALK1 residues are located near or within the two
loops of ALK1 that have significantly different conformation
ALK6
ALK3
ALK2
ALK1
ALK6
ALK3
ALK2
ALK1 367
363
429
424
a
b
Finger 1
Finger 2
Side view Top view
G405
V406
T408
F411
S339
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I335
K379
K368
G415 E420
E420T365
P366
T325
E351
F411 T408
V406
G405
S339
D338
I335
K379
G415
T365
c
Fig. 3 Specificity determinants in the BMP9 and BMP10 subfamily. a Sequence alignment of representative ALK-binding BMPs. GF-domain sequences of
ALK1-binding BMP9 and BMP10, ALK6-binding BMP14, ALK3-binding BMP2 and BMP4, as well as ALK2-binding BMP6 and BMP7 are aligned. Lines over
and below the sequences highlight the residues at the type I and type II receptor-binding surface based on BMP10:ALK1 and BMP9:ALK1:ActRIIb structures,
respectively. Asterisk (*) marks the residues that are conserved among at least 6 out of 7 aligned BMPs. Residues preferentially conserved between BMP9
and BMP10 are highlighted, in cyan for those at the type I site (conserved region 1), in blue for those at the type II site (conserved region 2) and in yellow
for those outside receptor binding surface (conserved region 3). BMP10 D338 and P366 are also highlighted in cyan because they make conserved
interactions with ALK1 in the crystal structure (Fig. 4). b Residues from conserved regions 1–3 plotted on BMP10 structure and labelled with full length
proBMP10 residue numbers. Fifteen residues from conserved regions 1–3 are shown in spheres, coloured accordingly. The first Gly from conserved region 3
is not modelled in the crystal structure, and hence not plotted. c An overlay of BMP10 (grey) onto the structures of BMP9 (gold, from 4FAO)9, BMP2
(green, from 2GOO)31 and BMP7 (cyan, from 1M4U)61 is shown from the side view (left) and the top view (right). The red arrows indicate the unique
insertion in BMP9 and BMP10.
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Fig. 4 Conserved region 1 and ALK1-specificity determinants. a ALK1-binding residues are mapped onto the BMP10 surface (grey), with those conserved
across all BMPs in Fig. 3a coloured in red, those from the BMP9 and BMP10 conserved region 1 in cyan, and other variable residues in yellow. b ALK1
(magenta cartoon) binding to BMP10 (surface), with residues interacting with BMP10 shown in sticks. c–f Detailed interactions between BMP10 and ALK1.
g Sequence alignment of four BMP-binding type I receptors, ALK1, ALK2, ALK3 and ALK6, with the four specificity-determining residues in ALK1
highlighted in yellow. Loop 4 and loop 5 are the two loops surrounding the 310 helix (Supplementary Fig. 4). h Overlaid structures of BMP type I receptors.
The structure of ALK1 in the BMP10:ALK1 complex (magenta) is overlaid onto ALK1 in BMP9:ALK1 complex (PBD:4FAO, orange), ALK3 (PDB:2GOO, light
green) and ALK6 (PDB:3EVS, light grey). ALK1 residues highlighted in g are shown in sticks.
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from those loops in ALK3 and ALK6 due to a 2–3 amino acid
deletions (Fig. 4g, h and Supplementary Fig. 4). Therefore,
ALK1 specificity is maximised through the presence of specific
residues and through their unique display by shortening the
length of the loops on which these residues are positioned.
The type II receptor binding site and conserved region 2. Of the
BMP type II receptors, the structures for ActRIIa:BMP7
(PDB:1LX5)34, ActRIIa:BMP2 (PDB:2GOO)31, ActRIIb:BMP2
(PDB:2H62)35 and ActRIIb:BMP9 (PDB:4FAO)9 have been solved.
Analysis of the ActRIIb binding site on BMP9 revealed that 26
residues contributed significantly to the receptor-binding interface
(Fig. 3a, lines below the sequences). Similar to the type I receptor-
binding site, a subset of these residues, again mostly hydrophobic,
are highly conserved across different BMPs (Fig. 3a, * below the
sequences) and can be mapped to the centre of the type II surface
on BMP9 (Fig. 5a, red). The variable residues, specifically those
residues that differ between various BMP ligands (Fig. 5a, yellow),
as well as the conserved region 2 residues that are conserved in
BMP9 and BMP10 alone (Fig. 5a, blue), surround these conserved
residues. When comparing the electrostatic surface, the ActRIIb
binding site on BMP9 is mostly conserved in BMP10 (Fig. 5b),
consistent with a previous report that both ligands bind ActRIIb
with similar affinities9.
The most striking feature in the conserved region 2 is the
insertion of a hydrophobic residue, Y416 in BMP9 and F411 in
Finger 1
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e
Fig. 5 Conserved region 2 and type II site analysis. a ActRIIb-binding residues (based on PDB:4FAO, ActRIIb in semi-transparent cartoon) are mapped
onto BMP9 surface (grey), with those conserved across all BMPs in Fig. 3a coloured in red, those from conserved region 2 in blue, and other variable
residues in yellow. b Type II binding surface of BMP9 (left) and BMP10 (right), showing as electrostatic surface (generated in PyMOL, red representing
negatively charged and blue positively charged surface). ActRIIb is shown in orange, semi-transparent cartoon. c Residues from BMP9 conserved region 2
make three backbone β-sheet and one sidechain H-bond interactions with ENG (PDB:5HZW, ENG in green, BMP9 in cyan). BMP10 is overlaid onto BMP9
and shown in grey, with four conserved region 2 residues shown in blue spheres. Sidechains of other residues are omitted for clarity. d Sequence alignment
of human BMP10 prodomain (hBMP10_pro) with mouse BMP9 prodomain (mBMP9_pro) and human BMP9 prodomain (hBMP9_pro). Residues at the
BMP9-binding surface are highlighted in yellow and those that make direct interactions with BMP9 GF-domain are marked with *. Residues that make main
chain interactions are also marked with ^. Only the prodomain regions that interact with BMP9 GF-domain are shown, and full-length alignment of
hBMP9_pro and hBMP10_pro can be found in Supplementary Fig. 5. e Residues in conserved region 2 of BMP9 make four backbone H-bond β-sheet
interactions with prodomain (PDB:4YCG; prodomain in orange, BMP9 in cyan. BMP10 is overlaid on BMP9 and shown in grey. Four conserved BMP10
residues are in blue spheres).
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BMP10 (Fig. 3a, red arrow), located in the top strand of finger 1
(Fig. 3c, red arrows). This additional residue leads to a kink in
this β-strand of BMP9 and BMP10, resulting in a novel
conformation that allows BMP9 and BMP10 to form unique
interactions. For example, this β-strand is in the core interaction
site of BMP9 binding for ENG (Fig. 5c), making three backbone
H-bonds with ENG to form an anti-parallel extended β-sheet30.
In addition, the side chain of the conserved Thr (413 in BMP9
and 408 in BMP10) also forms a H-bond with that of ENG Q270,
hence further contributing to the specificity of ENG for BMP9
and BMP10 (Fig. 5c).
Another polypeptide that binds to this conserved strand of
BMP9 and BMP10 is the prodomain. PDBePISA analysis of the
pro-BMP9 structure (4YCG, mouse BMP9 prodomain bound to
human BMP9 GF-domain)29 revealed that BMP9 and prodomain
interactions are mostly derived from three areas of the
prodomain: the α2-helix, β1-strand and α5-helix (Fig. 5d). The
prodomain β1-strand makes four mainchain H-bond interactions
with the conserved region 2 in BMP9 to form an extended anti-
parallel β-sheet (Fig. 5e), which likely contributes to the majority
of the binding energy. Since the prodomains of BMP9 and
BMP10 are highly conserved, especially with respect to the
contact residues in the α2-helix, β1-strand and α5-helix (Fig. 5d
and Supplementary Fig. 5), the structure of pro-BMP10 is very
likely to resemble that of pro-BMP9.
Structure of pro-BMP9:ALK1 complex. It is interesting to note
that in the BMP9 prodomain, residues from the α5-helix that
bind to BMP9 are exclusively charged and only make side-chain
interactions (Fig. 5d). This helix interacts with BMP9 at the
ALK1-binding site, and its density is missing in one of the two
prodomain molecules in 4YCI29, one of the two pro-BMP9
structures in the Protein Data Bank. This raises the question of
whether ALK1 binding leads to displacement of the prodomain
from BMP9. Indeed, a two-step mechanism for pro-BMP9
binding to the cell surface has been proposed29, whereby ALK1
binding to pro-BMP9 causes the displacement of only the α5-
helix and subsequent type II receptor binding leads to the com-
plete prodomain displacement29. This theory would suggest the
presence of a pro-BMP9:ALK1 complex in the initial stages of the
signalling process. However, another report based on extensive
SPR and ELISA analyses concluded that the binding of ALK1
alone displaced the entire prodomain36. To address this directly,
we resolved the crystal structure of the human prodomain-bound
BMP9 in complex with ALK1 (pro-BMP9:ALK1) to 3.3 Å, pro-
viding insight into the interaction of a prodomain-bound ligand
with its high-affinity cognate receptor in the TGFβ superfamily.
The overall structure contains one copy of the BMP9 dimer,
two copies of the ALK1 ECD and two copies of the prodomain.
While the electron densities for BMP9 and ALK1 are excellent,
the prodomains have overall poorer densities, with one copy
heavily truncated and both copies missing the α5-helix (Fig. 6a
and Supplementary Figs. 6, 7). Regions of the prodomain that are
in direct contact with BMP9, including the α2-helix and β1-
strand, have good densities (Supplementary Fig. 6b). The ALK1
and BMP9 components of this complex overlay very well with
those in the BMP9:ALK1:ActRIIb complex structure (PDB:4FAO,
with mainchain RMSD of 0.603 Å across BMP9:ALK1 mainchain
atoms, Fig. 6b), suggesting that the BMP9 GF-domain in the pro-
BMP9 complex can bind to ALK1 as a rigid body with minimal
conformational change. As for the prodomain, the regions in
contact with the BMP9 GF-domain (α2-helix and β1-strand)
overlay well with the prodomain in 4YCG (Fig. 6c), whereas
regions distal to the GF-domain are missing or overlay poorly.
Overall the mainchain RMSD between the two prodomains in the
pro-BMP9:ALK1 structure is 0.533 Å, and with the two
prodomains in 4YCG, 0.666–0.678 Å (note that 4YCG contains
mouse prodomain which may contribute to the slightly higher
RMSD). Importantly, the mainchain extended β-sheet interac-
tions from the conserved region 2 are maintained in the pro-
BMP9:ALK1 structure (Fig. 6d), suggesting that the contacts from
the α5-helix may not be essential for the maintenance of BMP9:
prodomain interactions.
Solution study of the pro-BMP9 and ALK1 interaction. To
confirm that ALK1 ECD can form a ternary complex with full-
length pro-BMP9, we performed an analytical gel filtration study
using purified pro-BMP9 and ALK1 ECD (Fig. 6e–h). We have
recently shown that soluble endoglin (sENG) can displace the
prodomain effectively from the pro-BMP9 complex, with the
displaced prodomain readily detectable as a different peak by
analytical gel filtration37, so we included sENG with pro-BMP9 as
a control. As shown in Fig. 6e, f, pro-BMP9 and sENG alone
eluted at peaks 1 and 6, respectively. When pro-BMP9 was mixed
with 2-fold molar excess of ALK1, a pro-BMP9:ALK1 complex
could be detected under peak 2, with excess ALK1 eluting under
peak 3. The control experiment with a mixture of pro-BMP9 and
sENG showed the sENG:BMP9 complex eluted under peak 4 and
the dissociated prodomain eluted under a different peak (peak 5).
Furthermore, Western blots of the consecutive fractions with
anti-BMP9 prodomain antibody confirmed that mixing of pro-
BMP9 with ALK1 did not shift the peak of the prodomain,
whereas mixing pro-BMP9 with sENG led to a shift of the pro-
domain peak to later fractions that are smaller than 66 kDa
protein marker (Fig. 6e, g). Similarly, we detected the pro-BMP10:
ALK1 complex and excess ALK1 when mixing pro-BMP10 with
ALK1 (Supplementary Fig. 8a). Importantly, the prodomains in
the pro-BMP9:ALK1 and pro-BMP10:ALK1 complexes are in the
intact form, i.e., the α5-helix is still present, as confirmed by the
size of the prodomain on the SDS-PAGE (Fig. 6f and Supple-
mentary Fig. 8a). This study confirms that ALK1 can bind to the
full-length pro-BMP9 and pro-BMP10 complex without displa-
cing the entire prodomain (Fig. 6h). A similar conclusion can also
be drawn from the native gel analysis (Supplementary Fig. 8b).
Pro-BMP9 runs as three bands on the native PAGE: the GF-
domain (band 1), the prodomain (band 3) and the pro-BMP9
complex (band 2). Upon mixing with ALK1 ECD (band 4), newly
appeared bands containing the ALK1:BMP9 complex (band 5) as
well as the pro-BMP9:ALK1 complex (band 7) could be readily
detected.
CV2 does not inhibit BMP9 signalling. The conserved region 2
corresponds to the same region where CV2 binds to BMP2
(Fig. 7a)38. A detailed analysis of the CV2:BMP2 structure
(PDB:3BK3)38 revealed that CV2 forms four backbone H-bond
interactions with the same top strand of finger 1 in BMP2. Since
BMP9 and BMP10 have an insertion and adopt a different con-
formation in this strand, we hypothesised that CV2 would not be
able to interact with BMP9 as it does to BMP2, even though a
previous publication using a reporter assay suggests that CV2
inhibits BMP9 signalling11. We first tested whether CV2 could
inhibit BMP9 or pro-BMP9 signalling in the physiologically
relevant cell type PAECs; no CV2 inhibition was observed even
when CV2 was applied at a 250-fold molar excess using either a
Smad1/5 phosphorylation assay (Fig. 7b) or measuring ID1 gene
induction (Fig. 7c). As a positive control, we detected CV2
inhibition of BMP4 signalling in pulmonary artery smooth
muscle cells (PASMCs) at 10-fold or 20-fold molar excess using
the same protocol (Fig. 7d). To further confirm that CV2 is
capable of inhibiting BMP2 but not BMP9 signalling, we
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performed parallel BMP2 and BMP9 signalling assays in a single
cell type, C2C12 cells, by monitoring ALP induction. As shown in
Fig. 7e, both BMP2 and BMP9 induced robust ALP activity in
C2C12 cells. While the presence of CV2 inhibited BMP2-induced
ALP activity potently and in a dose-dependent manner, no
inhibition was detected for BMP9-mediated ALP induction.
These cell assays verified our structural analysis that CV2 does
not inhibit BMP9 signalling.
Modifying BMP9 signalling specificity by mutagenesis. Our
structural and sequence analyses suggest that protein–protein
recognition between BMPs and their receptors is regulated by a
tripartite mechanism, whereby one set of residues are conserved
across all BMPs, a second set are conserved within each BMP
subfamily and the remaining residues are unique for each BMP
ligand. This would suggest that the interface residues that are not
conserved between BMP9 and BMP10 likely contribute to the
features that vary between the two ligands. It has been shown that
BMP9 is very potent in inducing ALP activity in C2C12 cells
in vitro and heterotopic bone formation in vivo, whereas BMP10
does not have such activities39. We therefore questioned whether
it is possible to generate variants of BMP9 with less or no
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osteogenic activity by mutating non-conserved interface residues
from BMP9 to BMP10 (those highlighted in yellow in Fig. 4a).
Indeed, 4 out of the 7 mutants showed reduced ALP-induction
activity in C2C12 cells compared to wild type (WT) BMP9, in
particular F362Y and D366E mutations results in complete loss of
BMP9-induced ALP activity under the experimental conditions
(Fig. 8a). A similar pattern was also observed when monitoring
the Id1-gene induction by BMP9 and its variants in C2C12 cells
(Supplementary Fig. 9). We further measured type I receptor
binding affinities of BMP9, BMP10 and the BMP9 variant D366E
which has lost ALP-induction activity in C2C12 cells. As shown
in Supplementary Fig. 10, pro-BMP9, pro-BMP9 D366E and pro-
Fig. 6 ALK1 can form a complex with pro-BMP9. a Overall structure of the human pro-BMP9:ALK1 complex at 3.3 Å (BMP9 in green, ALK1 in magenta,
prodomain in orange) overlaid onto the pro-BMP9 structure (4YCG, grey, semi-transparent). b Backbones of the BMP9:ALK1 portion from the pro-BMP9:
ALK1 structure (BMP9 in green, ALK1 in magenta) overlaid onto the same region in the BMP9:ALK1:ActRIIb structure (4FAO, grey). c Overlay of the two
prodomains from the pro-BMP9:ALK1 structure (shown in cartoon and coloured in orange and grey respectively) and that from 4YCG (in ribbon, cyan).
d In the pro-BMP9:ALK1 structure, the conserved region 2 in BMP9 makes the same four backbone H-bond interactions with the prodomain as shown in
Fig. 5e. Four residues in the conserved region 2 are shown in blue spheres and labelled with BMP10 numbering. e–h Analysis of complex formation by
analytical gel filtration. Purified pro-BMP9, pro-BMP9 mixed with ALK1, pro-BMP9 mixed with sENG and sENG were run separately on an S200 10/300 gel
filtration column which was pre-equilibrated with 20mM Tris.HCl, 150mM NaCl, pH 7.4. e Gel filtration traces. The arrows indicate the elution volumes of
the standards. Numbers 1-6 indicate the 6 peaks which were analysed by SDS-PAGE. fMiddle fraction from each peak was run on an SDS-PAGE. Identities
of the proteins on the SDS-PAGE are indicated using coloured circles. g Consecutive fractions from each gel filtration experiment were run on a non-
reducing SDS-PAGE and immunoblotted using an anti-BMP9 prodomain antibody. Each analytical sample run was repeated at least one more time with
fraction checked on SDS-PAGE to ensure reproducibility. h Cartoon diagrams, using the same colouring scheme as the circles in f, to illustrate that mixing
pro-BMP9 with ALK1 leads to the formation of pro-BMP9:ALK1 complex, whereas mixing pro-BMP9 with sENG leads to the displacement of the prodomain
which can be readily detected as a different peak in the gel filtration.
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BMP2:CV2 structure (PDB:3BK3, CV2 in magenta and BMP2 in green). Four mainchain H-bonds that stabilise the BMP2:CV2 β-sheet interaction are
shown. BMP9 has the same conformation as BMP10 in this region. b, c CV2 does not inhibit BMP9 signalling in PAECs. Serum-starved PAECs were treated
with BMP9 or pro-BMP9 (at 1 ng ml−1 GF-domain concentration) without or with CV2 at 10-fold, 20-fold, 50-fold or 250-fold molar excess for 15min to
assess Smad1/5 phosphorylation using immunoblots (b) or for 1 h to assess ID1 gene expression using qPCR (c). One representative of three independent
experiments is shown in b. Band intensity was quantified using Image J (version 1.51s). d CV2 inhibits BMP4 signalling in PASMCs. Serum-starved PASMCs
were treated with BMP4 (25 ngml−1) without or with CV2 at indicated molar excess for 15 min. Immunoblots and quantification were carried out as above.
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were analysed (see Methods section). N= 7 independent experiments. For all panels, means ± SEM are shown. d, e One-way ANOVA for each BMP
treatment group, Dunnett’s post hoc analysis against BMP alone-treated controls. Source data are provided as a Source Data file.
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BMP10 all bind to ALK1-Fc with similar affinities. But for
binding to the ALK2-Fc, we can only detect the binding of pro-
BMP9 and BMP9 GF-domain, not pro-BMP10 or pro-BMP9
D366E, confirming the D to E mutation at position 366 of BMP9
abolishes its ability to bind ALK2. Since BMP10 was shown to be
non-osteogenic in vivo39, we subjected pro-BMP9 D366E to an
in vivo osteogenic assay, along with BMP2 GF-domain, pro-
BMP9 and pro-BMP10 controls. To our surprise, in this in vivo
assay with purified recombinant proteins, not only did pro-BMP9
D366E induce bone-formation, but pro-BMP10 itself was also an
osteogenic BMP (Fig. 8b, c).
Discussion
The endothelial ALK1-mediated BMP signalling pathway has
attracted much attention due to its therapeutic potential for the
treatment of cardiovascular disease and solid tumour. Under-
standing the molecular details of this pathway will facilitate the
translation of therapies by improving their efficacy and specificity
whilst minimising unwanted side effects. In this study, we provide
essential insight into several key molecular details of the ligands
involved in this signalling pathway.
Firstly, although BMP9 and BMP10 circulate in their
prodomain-bound forms, most published signalling and func-
tional assays have utilised GF-domains due to the unavailability
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of pro-BMP9 and pro-BMP10 from commercial sources. We have
expressed full-length human BMP9 and BMP10 in mammalian
cells and purified the circulating forms of the ligands under native
conditions. We demonstrate that they are functionally equivalent
ligands on vascular endothelial cells in vitro and bind to ALK1
ECD with similar affinities. This provides a strong rationale that
pro-BMP10 could be administered like pro-BMP9 in treating
PAH23. However, it is worth noting that this study focused on
BMP9 and BMP10 with respect to ALK1-mediated signalling in
endothelial cells. At higher concentrations, both BMP9 and
BMP10 can signal through non-ALK1-dependent pathways40,41
and thus may have different signalling capacity and functional
consequences.
Secondly, by solving the crystal structure of the BMP10:ALK1
complex and comparing it to published structures, we have iden-
tified three regions that are highly conserved between BMP9 and
BMP10. The conserved region 1 accounts for ALK1 specificity. The
conserved region 2 defines the specificity for ENG, prodomain and
possibly the type II receptor as well. The conserved region 3 is
located in the middle part of the BMP dimer. The crystal structure
of pro-myostatin suggests that C-terminal part of the prodomain
could potentially interact with myostatin GF-domain residues in
this region42. A crystal structure of unprocessed proBMP9 or
proBMP10 will be required to address this question.
The type I and type II receptor binding sites have a common
feature in that each possesses residues that are conserved among
all BMPs (red surface in Figs. 4a, 5a), and residues that are
variable and determine BMP subgroup specificity. This is remi-
niscent of a well-characterised protein–protein recognition
between four colicin DNases and their cognate immunity pro-
teins. This family of closely related and structurally homologous
proteins achieve specificity by a dual recognition mechanism,
whereby a conserved region contributes to the major binding
energy whilst a variable region modifies the interaction by further
contributing positively in cognate interactions or negatively in
non-cognate interactions43,44. There are 15 BMP molecules in
humans, which signal through four type I and three type II
receptors. Therefore, more complicated mechanisms are required
for the regulation of specific protein–protein interactions within
the BMP system. We identified a tripartite mechanism here which
could explain the specificity between BMP-receptor interactions.
The 16 conserved residues in the conserved regions 1–3 identified
in this study distinguish BMP9 and BMP10 from other members
of the BMP family, in particular those within the type I site
determine the ALK1-signalling specificity.
In the crystal structure of the pro-BMP9:ALK1 complex, we
observed significant proteolysis of the prodomain (Supplemen-
tary Fig. 7). Although it is possible that the excessive proteolysis
was due to a crystallisation artefact, the digested regions do not
make direct crystal contacts and thus there is no evidence to
suggest that the proteolysis would favour crystal formation. We
speculate that the binding of ALK1 to pro-BMP9 may destabilise
the prodomain, rendering it more susceptible to proteolysis;
hence only the regions in direct contact with BMP9 are highly
ordered due to interaction restraints. Nevertheless, this structure
suggests that ALK1 ECD binding to pro-BMP9 does not lead to
the dissociation of the prodomain, in contrast to a previous
report36. We further validated this conclusion using analytical gel
filtration with sENG as a control37. Our result is in agreement
with Mi et al.29 that ALK1 binding only displace the α5-helix, not
the entire prodomain from BMP9.
Structural analysis of the conserved region 2 revealed a distinct
conformation adopted by BMP9 and BMP10 due to one amino
acid insertion, prompted us to question whether CV2 could
inhibit BMP9 and BMP10 signalling as reported previously11,12.
Using a range of cell-based signalling assays, we have conclusively
shown that CV2 does not inhibit BMP9 signalling. This obser-
vation has important translational implications; for instance, if
BMP9 is to be developed into a therapy for PAH, the presence of
any circulating ligand traps must be taken into account.
Finally, during the validation of the structural findings, we
performed mutagenesis of BMP9 to modify its specificity and
evaluated its osteogenic activity in vitro and in vivo. We found
unexpectedly that BMP10 is also an osteogenic BMP that can
promote heterotopic bone-formation in vivo, in contrast to a
previous report39. This is likely due to limitations in the meth-
odology employed in the previous study, whereby C2C12 cells
infected with adenoviral constructs containing the BMP10 gene
were used for the ALP activity and in vivo bone-forming assay. It
is not known in that study whether the BMP10 produced from
transfected C2C12 cells was fully processed and active. In our
study, we used purified, fully processed recombinant pro-BMP10
with activity validated in PAECs5. Importantly, our data also
demonstrate that lack of ALP activity in vitro does not necessarily
predict lack of osteogenic activity in vivo. More studies are
required to understand molecular mechanisms that determine the
bone-inducing activity of BMP9 and BMP10.
In summary, using a combination of signalling assays, protein
biochemistry and X-ray crystallography, we provide extensive and
detailed molecular insights into ALK1-mediated signalling by
circulating forms of BMP9 and BMP10. Such knowledge will
provide essential information for improving the specificity and
efficacy of therapies that target the endothelial BMP signalling
pathways.
Methods
Materials. Rabbit antibody against phospho-Smad1/5 (pSmad1/5, cat. No. 9516)
was purchased from Cell Signalling Technology. Mouse monoclonal anti-α-tubulin
(cat. No. T6199) was purchased from Sigma-Aldrich. Secondary anti-rabbit
horseradish peroxidase (HRP) antibody (cat. No. P0448) and anti-mouse HRP
antibody (cat. No. P0447) were both from Dako. Plasmid purification kits and
RNA extraction kits were purchased from Qiagen. DMEM and CDCHO media
were purchased from Thermo Fisher Scientific. Pulmonary artery endothelial cells
(PAECs, cat. No. CC-2530) and endothelial growth medium (EGM2) were pur-
chased from Lonza. HEK EBNA cells (cat. No. CRL-10852) and C2C12 cells (cat.
No. CRL-1772) were purchased from ATCC. Chromatography columns were
purchased from GE Healthcare. All crystallisation reagents were purchased from
Hampton Research Inc and Molecular Dimensions. Human GF-domains of BMP2,
BMP9 and BMP10, CV2, ALK1-Fc and ALK2-Fc were all purchased from R&D
Systems.
Expression and purification of the ALK1 ECD. Human ALK1 cDNA
(NM_000020) encoding amino acids 22-118 was cloned into pET39b (70090,
Novagen) between NcoI and NotI sites to create a fusion protein DsbA-(His)6-
ALK1 ECD. A TEV (Tobacco Etch Virus nuclear inclusion A endopeptidase)
protease cleavage site was introduced at the N-terminus of the ALK1 ECD to
facilitate release of the untagged ECD. The construct was confirmed by DNA
sequencing and transformed into bacterial strain Rosetta DE3 (70954, Novagen)
for protein expression. Cells were grown to mid-log phase followed by isopropyl
β-D-thiogalactopyranoside induction and further incubation at 22 °C overnight.
ALK1 ECD was purified from periplasmic fractions following the method descri-
bed previously for the BMPRII ECD5. Briefly, total periplasmic proteins were
extracted following the pET System Manual (Novagen) and His-tagged fusion
proteins were purified on a 5 ml nickel-nitrilotriacetic acid column (GE Health-
care). Fractions containing the fusion protein were pooled, dialysed into Tris
Buffered Saline, and incubated overnight with His-tagged TEV protease. The
mixture was passed through a pre-charged nickel-nitrilotriacetic acid column to
remove His-tagged DsbA and TEV protease. ALK1 ECD, which was in the flow-
through and wash solution, was concentrated and further purified by gel filtration
on a Superdex 75 column.
Expression and purification of pro-BMP9 and pro-BMP10. Full-length human
BMP9 cDNA was cloned into pCEP4 (V04450, Invitrogen) between HindIII and
XhoI sites and verified by DNA sequencing. Cloning of full length human pro-
BMP10, transfection and purification of pro-BMP9 and pro-BMP10 were achieved
following previously described protocols5. Briefly, pCEP4 constructs containing
either proBMP9 or proBMP10 were purified using Qiagen midi prep kit. HEK
EBNA cells were seeded in ten triple flasks and grown to 50–80% confluency before
being transfected using polyethylenimine. Serum-free CDCHO medium was
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applied from Day 2 and conditioned media were harvested every 3–4 days over
2 weeks. To facilitate the processing, human full-length furin cDNA, also cloned in
pCEP4, was co-transfected with proBMP10.
To purify pro-BMP9 or pro-BMP10, 5 l of conditioned medium was loaded
onto two tandemly linked 5 ml Hitrap Q columns, pre-equilibrated in 20 mM Tris.
HCl, pH7.4. After elution with NaCl gradient, fractions containing pro-BMP9 or
pro-BMP10 were identified on a non-reducing SDS-PAGE, pooled, concentrated
using VivaSpin columns (Sartorius) and loaded onto a HiLoad 16/600 Superdex
200 pg gel filtration column pre-equilibrated in 20 mM Tris.HCl, 50 mM NaCl.
Fractions containing target proteins were identified by SDS-PAGE and Coomassie
staining, further purified on a MonoP 5/200 GL column which was pre-
equilibrated in 20 mM Tris.Cl, pH7.4. After elution with NaCl gradient, target
proteins were pooled and subject to a final purification step on a Superdex 200
column, pre-equilibrated in 20 mM Tris.HCl, pH7.4, 150 mM NaCl.
Expression and purification of sENG. The expression and purification of sENG
have been described recently37. Briefly, residue 1–586 of human ENG cDNA was
cloned into pCEP4 with a C-terminal 6xHis tag and sequence was confirmed by
DNA sequencing. Plasmids containing sENG were transiently transfected into
HEK EBNA cells in DMEM containing 5% FBS before changing into CDCHO
expression media. Conditioned medium was harvested every 3–4 days for up to
2 weeks and used for purification. To purify sENG, 5 l of conditioned medium were
loaded onto a 5 ml HiTrap Excel column (GE Healthcare) pre-equilibrated in
Buffer A (50 mM TrisHCl, pH7.4, 500 mM NaCl, 5 mM imidazole). After wash,
sENG was eluted with 5–1000 mM imidazole gradient in buffer A. Fractions
containing sENG were identified on SDS-PAGE, pooled and dialysed against
50 mM Tris.HCl, pH7.4, 50 mM NaCl and then loaded onto a 5 ml HiTrap Q HP
column. After eluting with a NaCl gradient, fractions containing sENG were
identified by non-reducing SDS-PAGE, pooled and further purified on a Superdex
200 16/600 gel filtration column.
Endothelial cell signalling assays. Human PAECs were grown in EGM2 with
10% FBS until 90% confluent before undergoing quiescence for 16 h in EGM2 with
0.1% FBS. Cells were treated with GF-domains of BMP9 and BMP10, or pro-BMP9
and pro-BMP10 with detailed conditions described in legends to Figs. 1, 7, 8.
Immunoblotting and qPCR analyses were carried out as detailed below.
Immunoblotting for detecting Smad1/5 phosphorylation. Cell lysates were
quantified using Detergent Compatible (DC)™ Protein Assay Kit II (cat. No.
5000112; Bio-Rad) following which 40 μg of protein was loaded and fractionated
on a 10% SDS-PAGE. After transfer and blocking, the membranes were incubated
with anti-pSmad1/5 antibody (1:300 dilution) followed by wash and secondary
anti-rabbit HRP antibody (1:2000 dilution). After further wash and detection with
chemiluminescence reagents (GE Biosceince), the blots were washed in PBS and re-
probed with mouse anti-α-tubulin antibody (1:2000 dilution). After washing and
incubating with secondary anti-mouse HRP antibody (1:2000 dilution), the target
protein was revealed using chemiluminescence kit.
RNA extraction and qPCR analysis. At the end of the treatment, cells were washed
and snap-frozen. Total RNA was extracted using RNeasy Plus Mini kit and reverse
transcription was carried out using High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) following manufacturer’s instruction. The following primers
were used for the qPCR analysis: human ID1: 5′-CTGCTCTACGACATGAACGGC,
5′-TGACGTGCTGGAGAATCTCCA; human β-2-microglobulin (B2M): 5′-CTCGC
GCTACTCTCTCTTTCT, 5′-CATTCTCTGCTGGATGACGTG; The reactions were
carried out on a StepOnePlus™ cycler (Applied BioSystems) and the relative expres-
sion of ID1 was normalised to B2M using the ΔΔCT method, shown as fold-change
relative to control samples.
Microarray analysis. Four human PAEC lines were grown as described above and
treated with pro-BMP9 or pro-BMP10 (both at 0.3 ng ml−1 GF-domain final
concentration) for 1.5 h before cells were harvested for mRNA extraction.
Microarray experiments were performed at Cambridge Genomic Services, using a
human Gene 2.1 ST Array Plate (Affymetrix, Wooburn Green, UK) in combination
with WT PLUS amplification kit (Affymetrix) according to the manufacturer’s
instructions. Following data processing using package Oligo (version 1.40.2) in R
(version 3.3)45, normalisation was carried out using Robust Multichip Analysis
(RMA)46, and comparisons were performed using the limma package (version
3.32.1)47. The results were corrected for multiple testing using false discovery
rate (FDR).
Surface plasmon resonance analysis. Receptor-ligand binding experiments were
performed using the Biacore T100 biosensor (Biacore/GE Healthcare). ALK1-Fc or
ALK1 monomer was immobilised onto a Series S research grade CM5 sensor chip
by amine-coupling at a density of 800 or 270 resonance units, respectively. Flow
cell 1 was used as the blank reference cell for subtraction during analysis. For
kinetic measurements, a concentrated series of BMP9 GF-domain, pro-BMP9,
BMP10 GF-domain or pro-BMP10 were injected in duplicate over the flow cells at
a flow rate of 30 μl min−1 in a buffer containing 0.01M HEPES, pH7.4, 0.5 M
NaCl, 3 mM EDTA, 0.5 mgml−1 BSA and 0.01% (v/v) Surfactant P20 at 25 °C. The
binding surface was regenerated with 4M Guanidine Hydrochloride between each
cycle by four short injections (8 s each) at a flow rate of 30 μl min−1. The kinetic
rate constants were obtained by fitting the corrected data to a 1:1 interaction model
using Biacore T100 Evaluation Software (version 2.0.3, GE Healthcare). The
equilibrium binding constant KD was determined by the ratio of binding rate
constants kd/ka.
Structure of the BMP10:ALK1 complex. To purify the BMP10 GF-domain, pro-
BMP10 was denatured in 7M urea solution overnight before being loaded onto a
5 ml HiTrap S column equilibrated in a buffer containing 25 mM NaCl, 6 M urea
and 20 mM Tris pH 7.4. Bound proteins were eluted with a 25–1000 mM NaCl
gradient in 6M urea, 20 mM Tris pH 7.4. Fractions containing BMP10 GF-domain
disulphide-linked dimer were concentrated to 1 ml, then rapidly diluted with 19 ml
of cold refolding buffer (1 M NaCl, 10% glycerol, 3% CHAPS, 2.5% glycine, 5 mM
glutamic acid, pH4.0), and left to refold on a roller at 4 °C for 10 days. The refolded
mixture was subject to centrifugation and the supernatant containing soluble,
refolded BMP10 was recovered. Excess of purified ALK1 ECD was added directly to
BMP10 in the refolding buffer, further incubated at 4 °C overnight. The mixture
was then concentrated to 1 ml and applied to a Superdex 200 16/600 column pre-
equilibrated in 20 mM Tris pH 7.4 and 200 mM NaCl. Fractions containing
BMP10:ALK1 ECD were identified by SDS-PAGE and Coomassie staining, pooled
and concentrated to 1.2 mg ml−1 for crystallisation. Hanging-drop crystallisation
trials, using 1 μl protein and 1 μl reservoir solution, were set up and diffraction
quality crystals were obtained over 1 month in 17% PEG 3350, 0.175M NH4I, 0.1
M HEPES pH 7.8 at 22 °C. Crystals were cryo-protected in 30% glycerol, 19%
PEG3350, 0.175 M NH4I, 0.1 M HEPES pH 7.8 and flash-frozen in liquid nitrogen.
Data were collected at 100 K at Diamond Light Source (DLS) on Beamline I03 at a
wavelength of 0.9763 Å from a single crystal, and processed in space group P6522
to 2.8 Å using iMOSFLM48, Aimless49 and Scala50 in CCP4 suite (version 7.0-
macosx-x86_64)51. The structure was solved by molecular replacement using
Phaser52, with BMP9 and ALK1 in 4FAO as the search models. Model building was
carried out using Coot53, and refined using REFMAC554 and phenix.refine (version
1.11.1_2575)55. Validation was performed using MolProbity56. A second crystal
form was subsequently obtained from Morpheus 2 screen condition 48 diluted with
30% water, which includes 0.07 M Amino acids (0.014M DL-Glutamic acids
monohydrate; 0.014M DL-Alanine; 0.014M Glycine; 0.014M DL-Lysine mono-
hydrochloride; 0.014M DL-Serine), 0.07 M Buffer System 3 (0.07 M Tris(base)/
BICINE) pH 8.5, 35% Precipitant Mix 4 (9% v/v MPD, 9% w/v PEG1000, 9% w/
PEG3350). Data collection was carried out at I03 (DLS) from a single crystal. Data
was processed by DIALS57 and aimless in space group P6522 to 2.3 Å. The structure
was solved by molecular replacement using Phaser, with the 2.8 Å BMP10:ALK1
ECD structure as the search model. Model building, refinement and validation
were carried out as above. The dihedral angles of 96.59 and 97.16% of all amino-
acid residues for the 2.3 and 2.8 Å structures are in the favoured region and none in
the disallowed region. All the data collection, data reduction, structure determi-
nation and refinement statistics are shown in Supplementary Table 1. The coor-
dinates were deposited in the PDB with the access codes of 6SF1 (2.8 Å) and 6SF3
(2.3 Å). The two structures are almost identical, with small changes in some loop
area (Supplementary Fig. 2). The 2.3 Å resolution structure was used in the
structural analysis in the Results section.
Structure of the pro-BMP9:ALK1 complex. Purified pro-BMP9 was mixed with
ALK1 ECD in a 1:1.5 molar ratio and incubated for 30 min at room temperature,
following which the mixture was loaded onto a Superdex 200 16/600 column pre-
equilibrated in 150 mM NaCl, 20 mM Tris pH 7.4. Fractions containing the pro-
BMP9:ALK1 ECD complex were identified by SDS-PAGE and Coomassie staining,
combined and concentrated to 10 mgml−1 to set up crystallisation trials in
hanging-drops, using 1 μl protein and 1 μl reservoir solution. Diffraction quality
crystals were obtained by micro-seedings in 0.14 M K/Na tartrate, 14% PEG 3350
over 4 weeks at 22 °C. Data were collected at 100 K from a single crystal, cryo-
protected in 25% glycerol in 0.14M K/Na tartrate, 16% PEG 3350, at DLS on I04-1
at a wavelength of 0.9282 Å, processed in P61 to 3.3 Å. The structure was solved by
molecular replacement using the BMP9:ALK1 structure from 4FAO and mouse
prodomain from 4YCG as search models. Data processing, molecular replacement,
model building and refinement were carried out using the software packages as
described above. The dihedral angles of 95.72% of all amino-acid residues are in the
favoured region and none in the disallowed region. The coordinates were deposited
in the PDB with the access code 6SF2. All the data collection, data reduction,
structure determination and refinement statistics are shown in Supplementary
Table 1.
Structural analysis and sequence alignment. Structural analyses were performed
and figures generated using PyMOL (The PyMOL Molecular Graphics System,
Version 1.2r3pre, Schrödinger, LLC). For BMP10:ALK1 structure, the 2.3 Å
structure was used for generating the final figures. Sequence alignments were
performed using Clustal Omega58. Protein–protein interaction interfaces were
analysed using the PDBePISA server (https://www.ebi.ac.uk/pdbe/pisa/)33. The
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numberings for all proteins in the alignments and structures begin at the start of
the open reading frame i.e., Met1 of the signal peptide.
Analytical gel filtration. Purified pro-BMP9, sENG or pro-BMP10 (all at 100 μg)
was mixed with a 2-fold molar excess of purified ALK1 ECD (in 150 mM NaCl,
20 mM Tris pH 7.4) or buffer control to a final volume of 200 μl. Above mixtures,
alongside ALK1 ECD control, were run on a Superdex 200 10/300 size-exclusion
column and 250 μl fractions were collected. Peak fractions from each run were
assessed by SDS-PAGE, Coomassie or silver-staining. Traces were exported from
AKTA Unicorn 6 control software, then aligned and displayed using Prism
6 software.
PASMC isolation. PASMCs were obtained from the lung resection specimens from
the Papworth Hospital Research Tissue Bank. Ethical approval was obtained from
the NRES Committee East of England -Cambridge East (reference number: 18/EE/
0269). Informed consents were obtained from all donors. Isolation of PASMCs has
been described previously59. Briefly, lung sections containing small vessels (<2 mm
diameter) were obtained. The lung parenchyma is dissected away and small vessels
were cut into small pieces around 0.2 cm × 0.2 cm. The chopped vessel pieces were
transferred to a T25 flask in DMEM medium supplemented with 20% foetal calf
serum. Allowing approximately two weeks for cells to attach and expand before
passage. PASMC cell type was confirmed by the characteristic elongated mor-
phology and immunostaining with calponin antibody. A negative mycoplasma test
was obtained before the cells were used for the signalling assays. The PASMCs
isolated from three individuals were used in the signalling assays.
Signalling assays in PASMCs. PASMCs were cultured in DMEM media with 10%
FBS and antibiotics until 90% confluent before undergoing quiescence in DMEM
with 0.1% FBS for 48 h. Cells were treated with BMP4 GF-domain (25 ng ml−1) in
the presence or absence of CV2 at indicated concentrations for 15 min followed by
protein extraction and pSmad1/5 immunoblotting as described above.
C2C12 cell signalling assays. C2C12 mouse myoblast cells were cultured in
DMEM media supplemented with 10% FBS and antibiotics until about 70% con-
fluent. Treatment mixture containing BMP2 or BMP9 with or without CV2 at
indicated concentrations were made up to 1 ml with DMEM containing 0.25% FBS
and antibiotics, followed by 30 minutes incubation at room temperature. The cells
were washed twice with 1 ml DMEM containing 0.25% FBS before treatment
mixture applied. After 68 h, cells were snap-frozen using a dry ice ethanol bath and
lysed with cold lysis buffer (1% Triton X-100 in PBS) and two freeze-thaw cycles.
The cell lysates were collected and centrifuged at 17,000 × g for 5 min at 4 °C to
remove insoluble material. Protein quantification was performed on the cell lysates
using the DC™ Protein Assay Kit II (BioRad). ALP activity was measured using a
96-well plate. Duplicate wells were prepared with 20 μg of cell lysate protein in a
total of 50 μl lysis buffer before 100 μl of pNPP substrate was added (Sigma-
Aldrich) in 0.1 M glycine buffer, pH 10.4, containing 1 mM MgCl2 and 1 mM
ZnCl2. The plate was covered in foil and incubated at 37 °C for 30 min, following
which the absorbance was periodically read at 405 nm on a Microplate Reader.
BMP9 mutagenesis and in vitro signalling assays. A panel of BMP9 mutants
was generated by replacing specified residues at the type I receptor site with
equivalent residues from BMP10 using site-directed mutagenesis. Mutations were
verified by DNA sequencing. Mutant proteins, alongside WT pro-BMP9, were
expressed in HEK-EBNA cells in T25 flasks. Because mutations in the BMP9 GF-
domain may change the antibody binding epitope, current published ELISA
methods which use antibodies against the GF-domain are not suitable for quan-
tifying the mutant proteins in the transfected medium. On the other hand, pro-
domain and the GF-domain are produced from the same polypeptide chain and
processed in a 1:1 ratio, hence the ratio of prodomain of BMP9 mutant to WT in
the conditioned media will be identical to the ratio of mature GF-domains. We
therefore quantified Pro-BMP9 WT and mutant proteins in the conditioned media
from each transfection following a previously published method as below28. The
conditioned media were subject to two repeats of anti-prodomain Western blots
and the ratio of band intensity of mutants to WT calculated. The concentration of
WT BMP9 in the transfection medium was determined by ELISA using BMP9
from R&D Systems as standards. The concentrations of the mutant proteins were
calculated using the ratio obtained from anti-prodomain blots. Endothelial cell and
C2C12 cell signalling assays were carried out as detailed above. Fold changes
relative to the WT were quantified from three independent HEK-EBNA trans-
fection and quantification experiments. Means ± SEM are shown.
In vivo heterotopic ossification (HO) assay. All in vivo animal studies were
performed in accordance with the UK Home Office regulations (Project Licence:
PPL PAE2D0A13) and ethical approval was obtained from the University of
Cambridge’s Animal Welfare and Ethical Review Board.
Male C57/BL6 mice (Charles Rivers UK Ltd) of 7–8 weeks’ old were housed in
groups of four in individually vented cages with free access to food and water. After
an acclimatisation period of 10 days, they were anaesthetised with isoflurane in O2
before the implantation of reduced growth factor Matrigels (Corning, Growth
Factor Reduced, cat. No. 356231) loaded with purified pro-BMP9, pro-BMP9
D366E, pro-BMP10 or BMP2 GF-domain (from R&D Systems) into the mid belly
of the Quadriceps Femoris (QF) muscle. Because BMP9-induced heterotopic bone
formation requires local muscle damage which could be achieved by cardiotoxin
injection, we performed the bone formation assay in the presence and absence of
cardiotoxin60. Cardiotoxin (40 μl 10 μM from Naja Pallida, Latoxan, Portes les
Valence, France. cat. No. L8102) was injected two days prior to the Matrigel/BMP
implant in to the QF of one leg to induce local inflammation. Ex vivo
morphological analysis of heterotopic bone formation was carried out 14 days after
the BMP application by microCT (Bruker, SkyScan 1172). 3D MicroCT images
(Fig. 8c) were reconstructed from 180 radiograph projections using filtered back
projection in CTvox software (Bruker). The HO volume was calculated from
contiguous 5 μm thick coronal CT slices. The HO area per slice was measured by
importing the CT sections into ImageJ and the HO segmented from the
surrounding muscle and bone by lower and upper threshold techniques. The HO
volume was calculated from the measured area and the interslice thickness.
Sections of the tissues containing the heterotopic bone were examined by
Hematoxylin & eosin staining and Masson’s trichrome staining.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Coordinates and structure factors for all structures have been deposited to the Protein
Data Bank, with the accession numbers of 6SF1, 6SF2 and 6SF3. Microarray data have
been deposited to Gene Expression Omnibus, with the accession number of GSE134890.
The source data underlying Figs. 1a, 7b–e, 8a, b and Supplementary Fig. 9 are provided as
a Source Data file. All additional experimental data are available from the corresponding
author on request.
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